Reimagining cell therapy.
Founded in 2015, Arcellx engineers innovative immunotherapies using its proprietary ARC-SparX platform to develop safer, more effective cell therapies. The company focuses on hematologic cancers and autoimmune conditions, with programs in multiple myeloma and other indications.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountUnknown
Feb 2026
Jan 2024
Feb 2022
Apr 2021
Oct 2019
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Clinical-stage biopharmaceutical company developing oral therapies for serious skeletal and cardi...
Minneapolis-based clinical stage biotechnology company focused on the development of molecularly ...
